CD38 and Miyoshi myopathy: To take advantage of the unique properties of IgE antibodies as cancer therapeutics and to address unmet medical needs in MM, we now report, for the first time, the development of a new fully human anti-CD38 IgE as a potential targeted immunotherapy for MM.